KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Alnylam Pharmaceuticals (ALNY) EBT Margin (2016 - 2025)

Alnylam Pharmaceuticals (ALNY) has disclosed EBT Margin for 15 consecutive years, with 5.19% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBT Margin rose 3789.0% year-over-year to 5.19%, compared with a TTM value of 8.7% through Dec 2025, up 2549.0%, and an annual FY2025 reading of 8.7%, up 2549.0% over the prior year.
  • EBT Margin was 5.19% for Q4 2025 at Alnylam Pharmaceuticals, down from 22.46% in the prior quarter.
  • Across five years, EBT Margin topped out at 22.46% in Q3 2025 and bottomed at 153.59% in Q3 2022.
  • Average EBT Margin over 5 years is 53.14%, with a median of 43.34% recorded in 2023.
  • The sharpest move saw EBT Margin plummeted -4474bps in 2022, then skyrocketed 17367bps in 2023.
  • Year by year, EBT Margin stood at 100.68% in 2021, then surged by 39bps to 61.79% in 2022, then skyrocketed by 49bps to 31.31% in 2023, then dropped by -4bps to 32.7% in 2024, then soared by 116bps to 5.19% in 2025.
  • Business Quant data shows EBT Margin for ALNY at 5.19% in Q4 2025, 22.46% in Q3 2025, and 5.34% in Q2 2025.